Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Perphenazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | LMNA | P02545 | 8/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 7/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 6/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 6/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 6/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 6/20 | 1.00 |
| ▸ | HTR2A | P28223 | 6/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 6/20 | 1.00 |
| ▸ | HRH1 | P35367 | 6/20 | 1.00 |
| ▸ | DRD3 | P35462 | 6/20 | 1.00 |
| ▸ | HTR2B | P41595 | 6/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 5/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 5/20 | 1.00 |
| ▸ | HTR1A | P08908 | 5/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Perphenazine SCHEMBL8762197 | 1.00 | MAPT (1.00) | MAPTLMNAMAPK1CYP2D6CYP3A4 | |
| Perphenazine SCHEMBL29461866 | 1.00 | MAPT (1.00) | MAPTLMNAMAPK1CYP2D6CYP3A4 | |
| Perphenazine SCHEMBL42125 | 1.00 | MAPT (1.00) | MAPTLMNAMAPK1CYP2D6CYP3A4 | |
| Perphenazine SCHEMBL140891 | 0.99 | MAPT (0.98) | MAPTLMNAMAPK1CYP2D6CYP3A4 | |
| Perphenazine SCHEMBL145754 | 0.99 | MAPT (0.98) | MAPTLMNAMAPK1CYP2D6CYP3A4 | |
| Perphenazine SCHEMBL29846305 | 0.99 | MAPT (0.98) | MAPTLMNAMAPK1CYP2D6CYP3A4 | |
| Perphenazine SCHEMBL5307579 | 0.96 | MAPT (0.91) | MAPTLMNAMAPK1CYP2D6CYP3A4 | |
| Perphenazine SCHEMBL28086447 | 0.96 | MAPT (0.91) | MAPTLMNAMAPK1CYP2D6CYP3A4 | |
| Perphenazine SCHEMBL28456705 | 0.94 | MAPT (0.88) | MAPTLMNAMAPK1CYP2D6CYP3A4 | |
| Perphenazine SCHEMBL8014634 | 0.94 | MAPT (0.88) | MAPTLMNAMAPK1CYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748885-A1 | POLYCARBONATE COMPOSITIONS HAVING IMPROVED TRANSMITTANCE AND DUCTILITY PROPERTIES | SHPP Global Technologies B.V. (NL) | 2026-05-27 | — | — | EP | claimed |
| US-20250084247-A1 | Polycarbonate Compositions with Flame Retardant Properties for Laser Activating Plating Processes | SHPP GLOBAL TECHNOLOGIES B.V. (NL) | 2025-03-13 | — | — | US | claimed |
| EP-4444797-A1 | POLYCARBONATE COMPOSITIONS WITH FLAME RETARDANT PROPERTIES FOR LASER ACTIVATING PLATING PROCESSES | SHPP Global Technologies B.V. (NL) | 2024-10-16 | — | — | EP | claimed |
| CN-118525059-A | Polycarbonate compositions with flame retardant properties for laser activated plating processes | 高新特殊工程塑料全球技术有限公司 | 2024-08-20 | — | — | CN | claimed |
| WO-2023131915-A1 | POLYCARBONATE COMPOSITIONS WITH FLAME RETARDANT PROPERTIES FOR LASER ACTIVATING PLATING PROCESSES | SHPP GLOBAL TECHNOLOGIES B.V. (NL) | 2023-07-13 | — | — | WO | claimed |
| EP-4209553-A1 | POLYCARBONATE COMPOSITIONS WITH FLAME RETARDANT PROPERTIES FOR LASER ACTIVATING PLATING PROCESSES | SHPP Global Technologies B.V. (NL) | 2023-07-12 | — | — | EP | claimed |
| US-11649357-B2 | Laser platable thermoplastic compositions with good flame retardancy, high heat property and good ductility and shaped articles made therefrom | SHPP GLOBAL TECHNOLOGIES B.V. (NL) | 2023-05-16 | — | — | US | claimed |
| US-20220062291-A1 | COMPOSITIONS AND METHODS OF TREATING CANCERS BY ADMINISTERING A PHENOTHIAZINE-RELATED DRUG THAT ACTIVATES PROTEIN PHOSPHATASE 2A (PP2A) WITH REDUCED INHIBITORY ACTIVITY TARGETED TO THE DOPAMINE D2 RECEPTOR AND ACCOMPANYING TOXICITY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-03-03 | — | — | US | claimed |
| EP-4748885-A1 | POLYCARBONATE COMPOSITIONS HAVING IMPROVED TRANSMITTANCE AND DUCTILITY PROPERTIES | SHPP Global Technologies B.V. (NL) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026099586-A1 | DRY POWDER FORMULATIONS | NANOPHARM LIMITED (GB) | 2026-05-15 | — | — | WO | disclosed |
| US-12569486-B2 | Calmodulin inhibitors, CHK2 inhibitors and RSK inhibitors for the treatment of ribosomal disorders and ribosomapathies | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2026-03-10 | — | — | US | disclosed |
| US-12565563-B2 | Halogen-free synergist | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2026-03-03 | — | — | US | disclosed |
| EP-4690102-A1 | METHOD AND COMPOSITIONS FOR ANALYZING TOXICITY IN ORGANISMS | vivoVerse, LLC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12523664-B2 | Sensor chip and methods thereof | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2026-01-13 | — | — | US | disclosed |
| WO-2022094615-A1 | COMPOUNDS AND METHODS FOR INCREASED ANTISENSE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022055285-A1 | PHARMACEUTICAL COMPOSITION FOR KILLING CANCER PROGENITOR CELLS | 연세대학교 산학협력단 | 2022-03-17 | — | — | WO | disclosed |
| CN-107750177-B | Use of antistatic materials in airways for hot aerosol condensation processes | 艾利斯达医药品公司 | 2022-03-11 | — | — | CN | disclosed |
| US-20220062291-A1 | COMPOSITIONS AND METHODS OF TREATING CANCERS BY ADMINISTERING A PHENOTHIAZINE-RELATED DRUG THAT ACTIVATES PROTEIN PHOSPHATASE 2A (PP2A) WITH REDUCED INHIBITORY ACTIVITY TARGETED TO THE DOPAMINE D2 RECEPTOR AND ACCOMPANYING TOXICITY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-03-03 | — | — | US | disclosed |
| US-20220062291-A1 | COMPOSITIONS AND METHODS OF TREATING CANCERS BY ADMINISTERING A PHENOTHIAZINE-RELATED DRUG THAT ACTIVATES PROTEIN PHOSPHATASE 2A (PP2A) WITH REDUCED INHIBITORY ACTIVITY TARGETED TO THE DOPAMINE D2 RECEPTOR AND ACCOMPANYING TOXICITY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-03-03 | — | — | US | disclosed |
| CN-114042074-A | Combined medication method for synergistically treating human brain glioma | 东南大学 | 2022-02-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569486-B2 | Calmodulin inhibitors, CHK2 inhibitors and RSK inhibitors for the treatment of ribosomal disorders and ribosomapathies | RPS6KA1, RPS6KA2, RPS6KA3 | DRD2 3909/4885MAPT 2118/4885LMNA 1109/4885 |
| US-20220062291-A1 | COMPOSITIONS AND METHODS OF TREATING CANCERS BY ADMINISTERING A PHENOTHIAZINE-RELATED DRUG THAT ACTIVATES PROTEIN PHOSPHATASE 2A (PP2A) WITH REDUCED INHIBITORY ACTIVITY TARGETED TO THE DOPAMINE D2 RECEPTOR AND ACCOMPANYING TOXICITY | PPP2CA, PPP2R2A, PPP3CA | DRD2 619/4885MAPT 2082/4885LMNA 4630/4885 |
| US-12565563-B2 | Halogen-free synergist | PPOX, PFAS, DUOX2 | DRD2 2172/4885MAPT 952/4885LMNA 4272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.